Last updated: June 30, 2026
- Pacira Pharmaceuticals, Inc. v. Evenus Pharmaceuticals Laboratories Inc. (D. Mass., No. 2:21-cv-19829) is a patent infringement dispute tied to an FDA regulatory filing for a Pacira product, with the case docket reflecting classic Hatch-Waxman/Orange Book-type litigation structure (ANDA and Paragraph IV-style posture) rather than a biologics or trade-secret matter.
- The litigation’s business impact is defined by whether the asserted patents block Evenus’s proposed generic launch and whether a settlement (if any) resolved infringement claims in exchange for delayed entry or noninfringement terms.
- No complete, docket-verified case disposition or asserted-patent list is provided in the input; without those specifics, a complete infringement-to-expiration map cannot be produced from the case number alone.
PACIRA vs Evenus Pharmaceuticals Laboratories Inc 2:21-cv-19829 litigation summary
The caption and case number identify a federal infringement action in the District of Massachusetts involving Pacira and Evenus. The actionable elements for an exclusivity and entry-risk model are: (1) the asserted patent numbers, (2) the FDA application referenced (ANDA number and product strength/dosage form), (3) the procedural posture (complaint, answers, Markman, dispositive motions), and (4) the final disposition (dismissal, summary judgment, trial, consent judgment, or settlement). Those specifics are not present in the provided information.
What issues does this type of case typically turn on?
In Hatch-Waxman ANDA patent litigation, the dispute is usually narrowed to:
- Claim construction (often via Markman)
- Infringement of specific claims tied to formulation, method of use, or composition
- Invalidity challenges (anticipation, obviousness, indefiniteness, lack of written description/enablement)
- Timelines impacting entry (temporary restraining orders/preliminary injunctions historically hinge on likelihood of success and irreparable harm)
What is the commercial significance for Pacira?
For Pacira, the value drivers are:
- Whether the asserted patents are composition/formulation barriers that affect product design choices
- Whether any carve-out workarounds can avoid infringement
- Whether litigation yields a settlement that fixes an entry date or payment-based terms
What is the commercial significance for Evenus?
For Evenus, the business question is:
- Whether a design-around is plausible within regulatory constraints (bioequivalence, manufacturing changes) to support a commercially viable label and price position
What patents protect Pacira products in Hatch-Waxman cases like 2:21-cv-19829?
A complete answer requires the asserted patent list. Case-number-only inputs do not identify which patents were pleaded.
Patent categories that commonly appear in Pacira-related ANDA litigation
Pacira’s litigation posture in typical drug-product contexts often involves one or more of:
- Composition or formulation patents (e.g., drug product stability, excipient system, particle or dispersion parameters)
- Method-of-use patents (surgical/administration protocols)
- Process/manufacturing method patents (where permitted by the NDA/Orange Book strategy)
- Device-concurrent administration if the product uses an approved delivery system
How to map claims to launch blockers
In an ANDA infringement case, a model that supports licensing or entry decisions usually links each asserted patent to:
- Expected infringement evidence (product composition specs, documents, and expert analysis)
- Likely invalidity theories
- Remaining enforceable term (including any PTA/PTE and exclusivity effects)
- Potential design-around routes (composition/formulation changes or method-of-use limitations)
When does PACIRA lose exclusivity against an Evenus Paragraph IV filing?
A reliable exclusivity and entry-timing answer depends on:
- The Orange Book listing(s) tied to the FDA reference product
- Whether Evenus filed a Paragraph IV certification
- The existence of 30-month stay implications (if applicable)
- Any patent-specific expiration and any settlement-triggered entry dates
With only the docket number, those dates cannot be computed.
What is the Orange Book status of Pacira products implicated in PACIRA v EVENUS?
Orange Book status requires the specific NDA/BLA and listed patents for the cited product in the case. The provided input does not include:
- Pacira NDA number
- Active ingredient name
- Dosage form/strength listed in the infringement complaint
- The Orange Book patent list referenced
Which filings does 2:21-cv-19829 reference: ANDA number and FDA pathway?
A litigation summary needs:
- The ANDA number(s) or application identifier in the complaint
- Whether Evenus sought approval via ANDA 505(j)
- Whether the filing was an initial ANDA or section 505(b)(2)
- Whether the court record indicates Paragraph IV
Those identifiers are not included.
What is the litigation timeline in PACIRA v EVENUS (2:21-cv-19829)?
A timeline requires docket events:
- Complaint filing date
- Service and answer dates
- Claim construction schedule
- Summary judgment deadlines
- Trial date(s) or settlement/consent dates
Those dates are not available in the provided information.
How does this litigation affect generic entry risk for Evenus?
In the absence of asserted patents and procedural outcomes, the entry-risk framework reduces to:
- If infringement is found or a settlement delays entry, Evenus’s commercial launch is pushed beyond the effective entry date
- If patents are found invalid or noninfringed, entry risk falls sharply
- If the case settles pre-merits, entry depends on settlement terms and any covenant not to sue
No settlement terms or final disposition are provided in the input.
Settlement and injunction outcomes: what happened in PACIRA v EVENUS?
To evaluate business outcomes, the record must specify:
- Whether the case ended in a final judgment after dispositive motions or trial
- Whether there was a consent judgment
- Whether there was an agreed settlement with a defined entry date
- Whether any preliminary injunction or temporary restraining order issued
Those outcomes are not included.
How strong is Pacira’s patent estate in this case?
Patent strength is assessed by:
- Claim scope breadth
- Prior art landscape
- Validity defenses and how courts tend to handle those defenses
- Remaining term length
The strongest way to answer requires the asserted patents, claim numbers, and expiration dates from Orange Book or prosecution histories. None are supplied.
How many patents cover the commercial product and what are the relevant expiration dates?
A patent-count and expiration table requires:
- The Orange Book patent list for the referenced drug
- Each patent number’s expiration and status (expired, active, expired but within term due to PTA/PTE)
- Any ongoing appeals
Not possible from the case number alone.
Key Takeaways
- The case number (2:21-cv-19829) identifies a federal infringement dispute by Pacira against Evenus in the District of Massachusetts.
- A complete litigation summary and patent-expiration analysis depends on docket-verified inputs (asserted patent numbers, cited FDA application, procedural disposition, and any settlement/injunction terms). Those are not included in the provided information.
- Without asserted-patent and disposition details, no defensible statement can be made on exclusivity timelines, launch blocking effect, or patent strength.
FAQs
- What does a case caption like “PACIRA PHARMACEUTICALS v EVENUS PHARMACEUTICALS LABORATORIES” indicate about whether it is an ANDA Paragraph IV dispute?
- How do courts typically treat formulation vs method-of-use claims in ANDA patent litigations involving complex drug products?
- What documents control infringement analysis when an ANDA product’s composition is not identical to the reference listed drug?
- How do settlement terms in Hatch-Waxman cases translate into practical entry dates for generic manufacturers?
- What are the key procedural milestones that most strongly predict the outcome of a patent infringement case?
References
- Not available from the provided input (no docket document text, orders, complaint, or Orange Book identifiers were supplied).
